Navigation Links
Chiltern Announces Additional Investment in Endpoint
Date:6/16/2011

cessed via the phone, web, or mobile device.  

Company profilesChiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs around 1,300 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. www.chiltern.com.

endpoint: endpoint is an innovative company dedicated to the development of the leading Interactive Response Technology (IVR/IWR) platforms for the life sciences industry. endpoint's founding team members have been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma and biotech companies for domestic and global  studies with experience across a broad range of therapeutic areas and global implementations. www.endpointclinical.com Contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.UK

USATel: +44 (0) 1753 512 000

Tel: +1 (423) 968 9533natalie.chong@chiltern.com

susan.ojanen@chiltern.comRich Mullikin, APRMarketing DirectorendpointUSATel: +1 (925) 779 9115Email: rmullikin@endpointclinical.com
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... 2015 Veracyte, Inc. (NASDAQ: VCYT ) ... and chief executive officer, will present at the Morgan ... at 10:30 a.m. ET in New York, ... webcast and subsequent replay may be accessed by visiting Veracyte,s website ... shortly after conclusion of the presentation and archived on ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... ... 02, 2015 , ... Advancing in medical imaging processing technology ... monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ZEUS all-in-one ... with simultaneous access to high precision medical images and electronic health records. ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... SOPHIA ANTIPOLIS, France, February 26 NicOx,S.A. (NYSE ... for,full year 2008 and provided an overview of ... investigational,drug for the treatment of the signs and ... Michele Garufi, Chief Executive Officer of NicOx, ...
... National Research Council,s National Institute (NINT) for Nanotechnology have ... of plastic solar cells (hybrid organic solar cells). The ... goal of intense interest for many of the world,s ... shortage of the ultra-high purity silicon and other materials ...
... MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints ... To Be Presented at ASCO,s 2009 Genitourinary Cancers Symposium ... with Dr. Howard Scher Today at 4:30 p.m. Eastern ... (Nasdaq: MDVN ) today announced the presentation ...
Cached Biology Technology:Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 2Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 3Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 4Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 5Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 6Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 7Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 8Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 9Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 10Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 11Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 12Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 13Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 14Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value 15University of Alberta and NINT researchers make solar energy breakthrough 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 5
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... North and South Carolina have seen a steady increase in ... alone, swine production generates approximately a quarter of the state,s ... farms leads to the problem of proper animal waste disposal. ... animal waste in anaerobic lagoons. They are primarily used to ...
... In a Memorandum of Understanding signed today, the ... (EMBL) formalise their desire to maintain and further develop ... renewed and strengthened Memorandum of Understanding between the European ... confident that it will set the stage for even ...
... is seeking a new way to help those who ... this isn,t "The King,s Speech," the Academy Award-winning film ... a stammer. Instead, Alexander Leonessa ( http://www.me.vt.edu/people/faculty/leonessa.html ) wants ... and others who have suffered paralysis of the vocal ...
Cached Biology News:Environmental impact of animal waste 2Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients 2Virginia Tech researcher seeks to use electrical stimulation to give voice to stroke patients 3
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
Standard Fluka For microscopy (Hist.) redox indicator...
... a combination of an orbital shaker and ... while providing gentle, thorough mixing without foaming. ... used for a variety of applications including ... immunoblots, staining/destaining, chromatography, etc. The VSN-5 Nutating ...
... state-of-the-art software for all your biopharmaceutical applications ... a single, scalable software package. The graphical ... the control of all Freedom instruments from ... 100 with one liquid handling arm up ...
Biology Products: